IL37 and inflammatory bowel disease: IL-12/23 inhibitors currently used in the clinic include risankizumab, guselkumab, tildrakizumab (targeting IL-23p19), and ustekinumab (targeting IL-12/IL-23p40) mainly for chronic inflammatory and autoimmune diseases such as psoriasis and inflammatory bowel disease.272–276 A recent review proposed IL-12/IL-23 or IL-23 inhibitors as potential interventional targets for the ongoing COVID-19 pandemic.277